Navigation Links
AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
Date:11/29/2007

WILMINGTON, Del., Nov. 29 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the United States (US) Food and Drug Administration (FDA) has granted an additional six-month period of exclusivity to market ARIMIDEX(R) (anastrozole) for its licensed breast cancer indications until June 2010. Prior to pediatric exclusivity being granted by the FDA, the patent was due to expire in December 2009.

ARIMIDEX is currently approved in the US for the for the following indications:

-- The adjuvant treatment (treatment following surgery with or without

radiation) of postmenopausal women with hormone receptor positive early

breast cancer (Sub Part H approval granted in 2002, final approval in

2005).

-- The first-line treatment of postmenopausal women with hormone receptor

positive or hormone receptor unknown locally advanced or metastatic

breast cancer (granted in 2000).

-- The treatment of advanced breast cancer in postmenopausal women with

disease progression following tamoxifen therapy. Patients with hormone

receptor-negative disease and patients who did not previously respond

to tamoxifen therapy rarely responded to ARIMIDEX (granted in 1995).

Dr. John Patterson, Executive Director of Development at AstraZeneca said "Pre-clinical and clinical data supported the investigation of the therapeutic potential of ARIMIDEX in pediatric conditions that manifest symptoms resulting from increased estrogen production, for example: gynecomastia in pubertal boys and precocious puberty in girls with McCune-Albright Syndrome (MAS). While pleased to have been able to work with the FDA in investigating the potential benefits of ARIMIDEX in these settings, AstraZeneca will not be seeking an indication in either of these pediatric conditions based on trial results."

In the US, ARIMIDEX sales reached $507 million for the nine months of 2007. ARIMIDEX has a
'/>"/>

SOURCE AstraZeneca
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. AstraZeneca Leads Local Walking Movement
2. AstraZeneca Joins Local Walking Movement
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
5. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
6. AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
11. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... V/NO (Virtually No Alcohol) Wines have a ... opening/closing and for reuse. Consumers simply twist the cup, turn ... Yorkers, professionals, and basically anyone can now enjoy a ... back socially or pair with meals at work, home, or ... wine and that means Napa Wine grapes undergo the ...
(Date:3/30/2015)... 30, 2015 South Coast Surety is pleased ... Bond Representative. Richard has been known to the management of ... Richard attended the University of Georgia, majoring in Banking and ... the sales and sales management of business equipment for a ... Most recently, Richard was a senior officer with a National ...
(Date:3/30/2015)... 30, 2015 Considered to be the ... in the global business community, this next generation of ... ante by managing big data and frameworks with virtually ... already powerful analytic and logic features are a technological ... of Lazarus Alliance said “The IT Audit Machine is ...
(Date:3/30/2015)... GREEN, Ohio (PRWEB) March 30, 2015 ... a globally recognized designer and manufacturer of ... and vinyl upholstery options. The new upholsteries ... laboratory, education and custom seating, providing disinfectable, ... are manufactured by renowned textile purveyor CF ...
(Date:3/29/2015)... 2015 Pro Ace Care Heating & ... now provide qualified HVAC technicians that will visit the ... and related systems throughout Vancouver, North Vancouver, Burnaby, Richmond, ... conditioners, heat pumps require regular maintenance from a professional. ... BC Hydro strongly suggest you have it serviced annually ...
Breaking Medicine News(10 mins):Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:Richard Ford Joins South Coast Surety Contract Surety Team 2Health News:Building on Success: Next Generation of Cyber Crime Prevention Unveiled! 2Health News:BioFit Adds Bleachable Upholstery Options to Seating Line 2Health News:Pro Ace Care Now Provides Qualified HVAC Technicians for Heat Pump Maintenance 2
... , , Mr. Randall Terry and ... city tour, where they held press conferences, performed street theatre, and ... HR 3200. More Details and links at www.OverturnRoe.com , , ... by Randall Terry, founder of Operation Rescue. , , ...
... WASHINGTON, Aug. 26 Loretta King, Acting Assistant Attorney General ... a federal grand jury in Denver has charged Donald Hertz ... the Freedom of Access to Clinic Entrances (FACE) Act for ... The FACE Act makes it a federal crime to injure, ...
... gut noted in study of people with type 1 version ... abnormal immune response to wheat proteins may contribute to type ... people with type 1 diabetes found that nearly half had ... identified genes associated with this abnormal immune response. , "The ...
... genes that may contribute to drug resistance in non-small ... in the open access journal BMC Cancer ... in drug sensitivity and resistance and actual in vitro ... UK, led a team of researchers who assessed the ...
... ... Association (DIA), in cooperation with FDA and PhRMA, will host Progression-Free Survival Oncology Workshop ... ... Drug Information Association (DIA), in cooperation with FDA and PhRMA, will host ...
... , INDIANAPOLIS, Aug. 26 ... gaming interests reported more than $3.6 million in lobbying expenditures ... Indiana public records. , , Individuals employed ... giving more than $228,000 to state political party committees and ...
Cached Medicine News:Health News:Randall Terry, Abortion, and Health Care: Terry comments on disruption of 'Health Care' Town Hall meeting. 'Yes: We disrupted Howard Dean's speech, and we would do it again. Obama and Pelosi must write into the bill: "No Abortion Funding; No mandates for 2Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 2Health News:DIA/FDA/PhRMA to Host Progression-Free Survival Oncology Workshop 3Health News:The Gaming Industry Stacks the Deck Against Smokefree Workplaces in Indiana 2
(Date:3/30/2015)... , March 30, 2015  BioDelivery Sciences ... the primary efficacy endpoint in the Phase 3 ... placebo for the treatment of painful diabetic neuropathy ... endpoints showed statistically significant improvement over placebo.  In ... was observed.  The results of this trial provide ...
(Date:3/29/2015)... TITUSVILLE, N.J. , March 29, 2015 /PRNewswire/ ... delayed time to relapse compared to placebo in ... 3 clinical study published this week in the ... (JAMA) Psychiatry . Results of ... recent New Drug Application (NDA) filing for three-month ...
(Date:3/27/2015)... /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") ... the issuance of an aggregate of 30,000 stock options ... aggregate of 120,500 stock options to employees and consultants ... three years and will be exercisable for a period ... per stock option. About Covalon Covalon ...
Breaking Medicine Technology:BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 2BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 3BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 4BioDelivery Sciences Announces Primary Endpoint in Phase 3 Study of Clonidine Topical Gel for Painful Diabetic Neuropathy Not Met, Though Encouraging Results Support Continued Development 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Covalon Announces Issuance of Stock Options 2
... Sequella, Inc., a clinical-stage biopharmaceutical company focused on ... announced that it received a $694,000 grant supplement as ... of 2009. The ARRA funds, issued through the National ... National Institute of Health (NIH), will assist Sequella to ...
... Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical ... ) focused on bringing the life saving potential ... nationwide and internationally, said today that it has retired ... of $212,959, $250,000 and $285,000. , On October 2, ...
Cached Medicine Technology:Sequella Receives American Recovery and Reinvestment Funding Through the NIH 2Cord Blood America Continues to Reduce Debt; Three Notes Retired 2
... The Laserex Ultra Q is a ... that provides ophthalmologists with a precise, reliable ... pupillary membranectomy. The system can be ... or opacification of the capsule (posterior capsulotomy), ...
... Laserex Ultra Q is the fundamental capsulotmy laser ... energy delivery and provides 2855% less energy in ... mJs in contemporary systems. This technology eliminates ... the risk of IOL pitting. , , ...
... high-end, mobile ultrasound imaging system. Its Ultrasonix ... amount of processing power for generating images ... imaging systems provide excellent image quality in ... Doppler, Color Doppler Color Angio, Color M-mode, ...
Protects the eye during or after surgery or trauma. Clear window dressing. Protects the eye allowing the patient to see....
Medicine Products: